Articles

Poll

Podcasts

Slideshows

Videos

Dermatology

The HCPLive dermatology page is a resource for medical news and expert insights on skin disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for dermatologic conditions, and more.

In this interview with Milaan Shah, MD, the expert consensus panel reviewing deucravacitinib’s safety and efficacy for psoriasis is discussed.

Efficacy, Safety of Deucravacitinib for Psoriasis, with Milaan Shah, MD

This interview from the 2025 New Wave Dermatology Conference features DiRuggiero discussing challenging psoriasis cases and tips for healthcare providers.

Dealing with Difficult or Unique Psoriasis Cases, with Douglas DiRuggiero, DMSc, MHS, PA-C

Discover innovative treatments for plaque psoriasis that cater to diverse skin tones, offering effective relief without the risk of discoloration.

Understanding Roflumilast Foam's FDA Approval for Scalp and Body Psoriasis, with Jennifer Soung, MD

This approval of roflumilast foam as a once-daily topical treatment for psoriasis of the scalp and body followed the phase 3 ARRECTOR study findings.

FDA Approves Once-Daily Roflumilast (ZORYVE) Foam 0.3% for Scalp and Body Psoriasis

AC-201 at 25, 50, and 100 mg doses show promising phase 2 results, significantly reducing psoriasis severity.

AC-201, an TYK2/JAK1 Inhibitor, Hits PASI-75 at Week 12 in Psoriasis Phase 2 Trial

This interview with Jennifer Soung, MD, highlights the implications of recent phase 3 findings on roflumilast foam 0.3% (Zoryve) for psoriasis of the scalp and body.

Phase 3 Findings on Roflumilast Foam 0.3% for Scalp and Body Psoriasis, with Jennifer Soung, MD

In this analysis, investigators looked at the extent to which psoriasis severity correlates with patients’ risk of developing sleep disorders.

Study Identifies Association Between Psoriasis, Sleep Disorders in National Cohort

This interview with Andrew Alexis, MD, MPH, highlights the unique clinical challenges of high-impact areas of psoriasis such as the scalp and hands.

Oral Therapies for High-Impact Areas in Psoriasis, with Andrew Alexis, MD, MPH

These data from the ICONIC-TOTAL trial program highlight icotrokinra’s use as a selective IL-23 inhibitor and its effectiveness in skin clearance for psoriasis.

New Phase 3 Data on Icotrokinra Suggest Efficacy for Genital, Scalp Psoriasis

These findings support the conclusion that switching between adalimumab biosimilars largely maintains efficacy for patients with psoriasis.

Study Supports Adalimumab Biosimilar Interchangeability for Patients with Psoriasis

The HCPLive plaque psoriasis page is a resource for medical news and expert insights on psoriasis. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for psoriatic disease, and more.

Plaque Psoriasis